ArticleAmerican journal of human genetics1996
Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma.
Article in American journal of human genetics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 103 citations in OpenAlex.
- Development and preliminary evaluation of a genetics education booklet for retinoblastoma.Journal of genetic counseling · 2025Article
- Analysis of uveal melanomas and paired constitutional DNA for exclusion of a BAP1-tumor predisposition syndrome.Familial cancer · 2023Article
- Retinoblastoma in twins: Risk assessment of genotypic variants.Indian journal of ophthalmology · 2021Article
- At What Age Could Screening for Familial Retinoblastoma Be Discontinued? A Systematic Review.Cancers · 2021Article
- Preimplantation genetic diagnosis for retinoblastoma survivors: a cost-effectiveness study.Reproductive biomedicine & society online · 2020Article
- Spectrum of mutations in theMolecular vision · 2019Article
- Retinoblastoma and Neuroblastoma Predisposition and Surveillance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- A stepwise strategy for rapid and cost-effective RB1 screening in Indian retinoblastoma patients.Journal of human genetics · 2015Article
- Spectrum of germ-line RB1 gene mutations in Malaysian patients with retinoblastoma.Molecular vision · 2015Article
- Rapid detection of RB1 recurrent mutations in retinoblastoma by ARMS-PCR.Journal of genetics · 2013Article
- Genotyping of Polymorphic Microsatellite Markers Linked to RB1 Locus in Iranian Population.Avicenna journal of medical biotechnology · 2012Article
- Clinical utility gene card for: retinoblastoma.European journal of human genetics : EJHG · 2011Article
- Identification of a mutation in exon 27 of the RB1 gene associated with incomplete penetrance retinoblastoma.Familial cancer · 2009Article
- Retinoblastoma in India : microsatellite analysis and its application in genetic counseling.Molecular diagnosis & therapy · 2007Article
- [Retinoblastoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2006Review
- Retinoblastoma: genetic testing versus conventional clinical screening in India.Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology · 2004Article
- Overview. Predictive DNA testing in ophthalmology.The British journal of ophthalmology · 2003Article
- Predictive DNA testing in ophthalmology: View 2.The British journal of ophthalmology · 2003Article
- Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma.American journal of human genetics · 2003Article
- At what age could screening for familial retinoblastoma be stopped? A register based study 1945-98.The British journal of ophthalmology · 2000Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare costs of molecular and conventional screening of retinoblastoma relatives, we evaluated the direct health care costs. With variables set at the most likely values (baseline), the expected cost (in 1994 Canadian dollars) of conventional screening was $31,430 for a prototype family consisting of seven at-risk relatives (three clinic exams and eight examinations under anaesthetic over the first 3 years of life for each relative). For the molecular strategy that involves looking for the RB1 gene mutation in the proband, testing the relatives for that mutation, and clinical follow-up similar to conventional strategy for relatives with mutation, the expected cost was $8,674, using baseline variables. Sensitivity analysis over the range of values for each variable revealed a significant saving of health care dollars by the molecular route, indicating the benefit of redirecting economic resources to molecular diagnosis in retinoblastoma.
Indexed as
Identifiers
8755916PMC1914748W1500719577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.